Clinical Trials Directory

Trials / Completed

CompletedNCT00619931

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Arena Pharmaceuticals · Industry
Sex
All
Age
19 Years – 45 Years
Healthy volunteers
Accepted

Summary

The APD791-002 study is designed primarily to evaluate the safety, tolerability, and pharmacokinetics of APD791 when administered for 7 days to healthy adult subjects.

Conditions

Interventions

TypeNameDescription
DRUGAPD791APD791 or matching placebo in escalating doses

Timeline

Start date
2008-01-01
Primary completion
2008-06-01
Completion
2008-06-01
First posted
2008-02-21
Last updated
2022-07-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00619931. Inclusion in this directory is not an endorsement.